Bogle Investment Management’s Akebia Therapeutics AKBA Stock Holding History

Bogle Investment Management’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-19,300	Closed	-$262K	–	226
2020 Q2	$262K	Buy	+19,300	New	+$200K	0.04%	271
2018 Q4	–	Sell	-68,076	Closed	-$601K	–	325
2018 Q3	$601K	Buy	+68,076	New	+$609K	0.04%	231
2017 Q4	–	Sell	-85,131	Closed	-$1.67M	–	282
2017 Q3	$1.67M	Buy	+85,131	New	+$1.31M	0.11%	173
2016 Q1	–	Sell	-18,585	Closed	-$240K	–	378
2015 Q4	$240K	Buy	+18,585	New	+$190K	0.02%	340
2015 Q3	–	Sell	-191,373	Closed	-$1.97M	–	359
2015 Q2	$1.97M	Buy	+191,373	New	+$1.63M	0.15%	179

Other funds holding AKBA

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bogle Investment Management's AKBA Position: Q3 2020 in Review

Bogle Investment Management sold out of Akebia Therapeutics (AKBA) in Q3 2020, closing a stake of 19,300 shares — an estimated $262K sold.

Bogle Investment Management first reported a position in AKBA in Q2 2015 and held it in 5 quarters. The position peaked at $1.97M in Q2 2015. 164 funds tracked by Wall St. Rank hold AKBA as of Q3 2020.

Bogle Investment Management reported no remaining Akebia Therapeutics position as of Q3 2020 after selling out during the quarter.
Bogle Investment Management sold 19,300 Akebia Therapeutics shares in Q3 2020, an estimated $262K.
Bogle Investment Management first reported a position in Akebia Therapeutics in Q2 2015 and held it in 5 quarters.
Bogle Investment Management's Akebia Therapeutics position peaked at $1.97M in Q2 2015.
164 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2020.

Based on Bogle Investment Management's 13F filing for Q3 2020, filed 12 Nov 2020.